BYNFEZIA PEN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for BYNFEZIA PEN (BYNFEZIA PEN).
Selective serotonin reuptake inhibitor (SSRI); potently inhibits serotonin reuptake at the presynaptic terminal, enhancing serotonergic neurotransmission.
| Metabolism | Hepatic via CYP2C19 and CYP2D6; also involves CYP3A4 and CYP1A2; active metabolite N-desmethylcitalopram (escitalopram) is less potent. |
| Excretion | Renal excretion accounts for approximately 70% of elimination, with about 30% of a dose excreted unchanged in urine. Biliary/fecal excretion accounts for approximately 30% of elimination. |
| Half-life | Terminal elimination half-life is approximately 6-8 hours in patients with normal renal function. This supports twice-daily dosing regimen. |
| Protein binding | Approximately 95-99% bound to plasma proteins, mainly to albumin. |
| Volume of Distribution | Volume of distribution is approximately 2-4 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Subcutaneous injection: Absolute bioavailability is approximately 60-80%. |
| Onset of Action | Subcutaneous injection: Onset of action is within 15-30 minutes for glycemic effects. |
| Duration of Action | Duration of action is approximately 8-12 hours after subcutaneous injection, allowing for preprandial dosing. |
Subcutaneously, 150 mg once daily.
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment required for GFR ≥30 mL/min. For GFR <30 mL/min, not recommended due to limited data. |
| Liver impairment | No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh class A or B). Not recommended in severe hepatic impairment (Child-Pugh class C) due to lack of data. |
| Pediatric use | Not approved for pediatric patients; safety and efficacy not established. |
| Geriatric use | No specific dose adjustment required, but caution due to potential comorbidities and increased sensitivity to anticholinergic effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for BYNFEZIA PEN (BYNFEZIA PEN).
| Breastfeeding | Bynfezia Pen is excreted into breast milk. The milk-to-plasma ratio has not been formally established in humans but is estimated from animal studies to be approximately 0.3–0.5 based on similar agents. Breastfeeding is generally not recommended due to potential for adverse effects in the infant (e.g., sedation, poor feeding). If used, monitor infant for drowsiness, weight gain, and developmental milestones. |
| Teratogenic Risk | Pregnancy category D. First trimester: Exposure associated with increased risk of major congenital malformations, particularly neural tube defects and cardiovascular anomalies. Second and third trimesters: Risk of fetal growth restriction, preterm birth, and diminished amniotic fluid volume. Antiepileptic drug levels should be monitored and maintained at the lowest effective dose. |
■ FDA Black Box Warning
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
| Serious Effects |
Concomitant use with MAOIs or within 14 days of MAOI therapy; concomitant use with pimozide; hypersensitivity to citalopram or escitalopram; history of prolonged QT interval or congenital long QT syndrome; concurrent use with linezolid or intravenous methylene blue.
| Precautions | Serotonin syndrome risk; QT interval prolongation (dose-dependent); abnormal bleeding (especially with NSAIDs/aspirin); activation of mania/hypomania; hyponatremia; discontinuation syndrome; angle-closure glaucoma risk; sexual dysfunction. |
| Food/Dietary | No significant food interactions. Take with or without food. Avoid excessive alcohol consumption due to increased risk of diabetic ketoacidosis. |
Loading safety data…
| Fetal Monitoring | Monthly monitoring of valproate serum trough concentrations (target: 50–100 mcg/mL for seizure control). Regular ultrasound to assess fetal growth and anatomy. Nonstress test or biophysical profile in third trimester. Monitor maternal liver function tests and platelet count every trimester due to potential hepatotoxicity and thrombocytopenia. Assess for signs of bleeding tendencies in neonate (vitamin K prophylaxis recommended). |
| Fertility Effects | Valproate has been associated with menstrual irregularities, anovulation, and polycystic ovary syndrome (PCOS) in women of reproductive age, potentially reducing fertility. In men, reversible decreases in sperm count and motility have been reported. Discontinuation may reverse these effects. |
| Clinical Pearls | BYNFEZIA PEN (bexagliflozin) is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. Monitor renal function before initiation and periodically; avoid use if eGFR persistently <30 mL/min/1.73 m2. Assess volume status in elderly or patients on diuretics due to risk of intravascular volume contraction. Check for ketoacidosis even with normal blood glucose levels; discontinue in patients requiring urgent surgery or with serious infections. Do not use in patients with type 1 diabetes or diabetic ketoacidosis. May increase LDL cholesterol; monitor lipid panel. |
| Patient Advice | Take exactly as prescribed; do not double dose if missed. · Drink plenty of water to prevent dehydration, especially in hot weather or exercise. · Do not take if you have type 1 diabetes or a history of diabetic ketoacidosis. · Seek immediate medical attention if you experience nausea, vomiting, abdominal pain, tiredness, or trouble breathing (signs of ketoacidosis). · Inform your doctor if you have kidney problems, low blood pressure, or are on diuretics. · Report any signs of genital or urinary tract infections (itching, burning, discharge, foul odor). · Check blood sugar regularly as directed. · Do not drink alcohol excessively as it may increase risk of ketoacidosis. · Store pen in the refrigerator; do not freeze. Discard after 28 days after first use. |